An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center
| Autor: | Frank Cirrone, Anne M. McDonnell, Donna Neuberg, David C. Fisher, Yang Feng, Audrea Szabatura, Daniel Voit, Christy S Harris, James E. Butrynski |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Lymphoma medicine.medical_treatment Encephalopathy Cancer Care Facilities Risk Factors medicine Humans Pharmacology (medical) Ifosfamide Adverse effect Antineoplastic Agents Alkylating Retrospective Studies Chemotherapy Brain Diseases business.industry Incidence (epidemiology) Incidence Cancer Retrospective cohort study Sarcoma Middle Aged medicine.disease Surgery Oncology Female Neurotoxicity Syndromes Cisplatin business medicine.drug |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 21(3) |
| ISSN: | 1477-092X |
| Popis: | Purpose Ifosfamide-induced encephalopathy is a neurotoxic adverse effect of ifosfamide chemotherapy. The objective of this study was to determine the incidence of encephalopathy in patients with lymphoma and sarcoma receiving ifosfamide chemotherapy and assess for potential risk factors that influence the incidence of encephalopathy. Methods A retrospective study of sarcoma and lymphoma patients receiving ifosfamide chemotherapy was performed at the participating institutions. Enrollment began 1 July 2011 and continued chronologically backwards until 100 sarcoma and 100 lymphoma patients were enrolled. Identification of ifosfamide-induced encephalopathy events was performed by reviewing provider documentation of ifosfamide infusions. Logistic regression was employed to determine associations between risk factors and ifosfamide-induced encephalopathy events. Results Of the 200 patients enrolled, 29 (14.5%) patients experienced encephalopathy. Ifosfamide-induced encephalopathy occurred more frequently in the sarcoma population than the lymphoma population (24 vs. 5 patients, p Conclusions This is the first study to demonstrate that patients with sarcoma experienced ifosfamide-induced encephalopathy more often than those with lymphoma. For all patients, predisposing factors for ifosfamide-induced encephalopathy included previous cisplatin exposure, concomitant opioids and CYP2B6 inhibitors. Laboratory values that increased ifosfamide-induced encephalopathy risk included low serum albumin, increased serum creatinine, and increased hemoglobin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|